BACKGROUND: Previously we assessed risk factors for FEV(1) decline in children and adolescents using the Epidemiologic Study of Cystic Fibrosis (J Pediatr 2007;151:134-139); the current study assessed risk factors in adults. METHODS: Risk factors for FEV(1) decline over 3-5.5 years for ages 18-24 and ≥25 years were assessed using mixed-model regression. RESULTS: Mean rates of FEV(1) decline (% predicted/year) were -1.92 for ages 18-24y (n=2793) and -1.45 for ages ≥25y (n=1368). For the 18-24y group, B. cepacia, pancreatic enzyme use, multidrug-resistant P. aeruginosa, cough, mucoid P. aeruginosa, and female sex predicted greater decline; low baseline FEV(1) and sinusitis predicted less decline. For the ≥25y group, only pancreatic enzyme use predicted greater decline; low baseline FEV(1) and sinusitis predicted less decline. CONCLUSIONS: Risk factors for FEV(1) decline in adults <25 years are similar to those previously identified in children and adolescents; older adults had few statistically significant risk factors.
BACKGROUND: Previously we assessed risk factors for FEV(1) decline in children and adolescents using the Epidemiologic Study of Cystic Fibrosis (J Pediatr 2007;151:134-139); the current study assessed risk factors in adults. METHODS: Risk factors for FEV(1) decline over 3-5.5 years for ages 18-24 and ≥25 years were assessed using mixed-model regression. RESULTS: Mean rates of FEV(1) decline (% predicted/year) were -1.92 for ages 18-24y (n=2793) and -1.45 for ages ≥25y (n=1368). For the 18-24y group, B. cepacia, pancreatic enzyme use, multidrug-resistant P. aeruginosa, cough, mucoid P. aeruginosa, and female sex predicted greater decline; low baseline FEV(1) and sinusitis predicted less decline. For the ≥25y group, only pancreatic enzyme use predicted greater decline; low baseline FEV(1) and sinusitis predicted less decline. CONCLUSIONS: Risk factors for FEV(1) decline in adults <25 years are similar to those previously identified in children and adolescents; older adults had few statistically significant risk factors.
Authors: C Schaedel; I de Monestrol; L Hjelte; M Johannesson; R Kornfält; A Lindblad; B Strandvik; L Wahlgren; L Holmberg Journal: Pediatr Pulmonol Date: 2002-06
Authors: Carlos E Milla; James F Chmiel; Frank J Accurso; Donald R VanDevanter; Michael W Konstan; Geoffrey Yarranton; David E Geller Journal: Pediatr Pulmonol Date: 2013-09-09
Authors: Peter G Middleton; Marcus A Mall; Pavel Dřevínek; Larry C Lands; Edward F McKone; Deepika Polineni; Bonnie W Ramsey; Jennifer L Taylor-Cousar; Elizabeth Tullis; François Vermeulen; Gautham Marigowda; Charlotte M McKee; Samuel M Moskowitz; Nitin Nair; Jessica Savage; Christopher Simard; Simon Tian; David Waltz; Fengjuan Xuan; Steven M Rowe; Raksha Jain Journal: N Engl J Med Date: 2019-10-31 Impact factor: 91.245
Authors: Anna C Zemke; Seyed Mehdi Nouraie; John Moore; Jordan R Gaston; Nicholas R Rowan; Joseph M Pilewski; Jennifer M Bomberger; Stella E Lee Journal: Int Forum Allergy Rhinol Date: 2019-06-04 Impact factor: 3.858
Authors: Audrey Tluczek; Anita Laxova; Adam Grieve; Anne Heun; Roger L Brown; Michael J Rock; William M Gershan; Philip M Farrell Journal: J Cyst Fibros Date: 2013-10-21 Impact factor: 5.482
Authors: Jeffrey S Wagener; Stefanie J Millar; Nicole Mayer-Hamblett; Gregory S Sawicki; Edward F McKone; Christopher H Goss; Michael W Konstan; Wayne J Morgan; David J Pasta; Richard B Moss Journal: J Cyst Fibros Date: 2017-10-31 Impact factor: 5.482